Promoter Methylation and Response to Chemotherapy and Radiation in Esophageal Cancer

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 6, 2006, Pages 701-708

  Hamilton, James P ^a   Sato, Fumiaki ^a   Greenwald, Bruce D ^a   Suntharalingam, Mohan ^a   Krasna, Mark J ^a   Edelman, Martin J ^a   Doyle, Austin ^a   Berki, Agnes T ^a   Abraham, John M ^a   Mori, Yuriko ^a   Kan, Takatsugu ^a   Mantzur, Carmit ^a   Paun, Bogdan ^a   Wang, Suna ^a   Ito, Tetsuo ^a   Jin, Zhe ^a   Meltzer, Stephen J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FISHER EXACT TEST; HUMAN; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PREDICTION; PROMOTER REGION; QUANTITATIVE ANALYSIS; RANK SUM TEST; STUDENT T TEST;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME;

EID: 33744745285     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.03.007     Document Type: Article

References (57)

1. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
2. Wang K.K., Wongkeesong M., and Buttar N.S. American Gastroenterological Association medical position statement. role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 128 (2005) 1468-1470
3. Shaheen N.J. Advances in Barrett's esophagus and Esophageal adenocarcinoma. Gastroenterology 128 (2005) 1554-1566
4. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
5. American Cancer Society. Cancer facts & figures (2005), American Cancer Society, Atlanta
6. Schulmann K., Sterian A., Berki A., et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24 (2005) 4138-4148
7. Das P.M., and Singal R. DNA methylation and cancer. J Clin Oncol 22 (2004) 4632-4642
8. Momparler R.L. Cancer epigenetics. Oncogene 22 (2003) 6479-6483
9. Eads C.A., Lord R.V., Wickramasinghe K., et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61 (2001) 3410-3418
10. Sato F., Shibata D., Harpaz N., et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 62 (2002) 6820-6822
11. Takahashi T., Suzuki M., Shigematsu H., et al. Aberrant methylation of Reprimo in human malignancies. Int J Cancer 115 (2005) 503-510
12. Brock M.V., Gou M., Akiyama Y., et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9 (2003) 2912-2919
13. Darnton S.J., Hardie L.J., Muc R.S., et al. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma. loss of expression correlates with poor prognosis. Int J Cancer 115 (2005) 351-358
14. Kawakami K., Brabender J., Lord R.V., et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92 (2000) 1805-1811
15. Kikuchi S., Yamada D., Fukami T., et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 11 (2005) 2954-2961
16. Catto J.W., Azzouzi A.R., Rehman I., et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23 (2005) 2903-2910
17. Martens J.W., Nimmrich I., Koenig T., et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65 (2005) 4101-4117
18. Fiegl H., Millinger S., Mueller-Holzner E., et al. Circulating tumor-specific DNA. a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65 (2005) 1141-1145
19. Radford I.R. Radiation response of mouse lymphoid and myeloid cell lines. Part I. Sensitivity to killing by ionizing radiation, rate of loss of viability, and cell type of origin. Int J Radiat Biol 65 (1994) 203-215
20. Radford I.R., Murphy T.K., Radley J.M., et al. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int J Radiat Biol 65 (1995) 217-227
21. Shinomiya N. New concepts in radiation-induced apoptosis. 'premitotic apoptosis' and 'postmitotic apoptosis'. J Cell Mol Med 5 (2001) 240-253
22. Ohki R., Nemoto J., Murasawa H., et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 275 (2000) 22627-22630
23. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
24. Kang D., Chen J., Wong J., et al. The checkpoint protein CHFR is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 156 (2002) 249-259
25. Shibata Y., Haruki N., Kuwabara Y., et al. CHFR expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 23 (2002) 1695-1699
26. Kobatake T., Yano M., Toyooka S., et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 12 (2004) 1087-1092
27. Shibata D.M., Sato F., Mori Y., et al. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res 62 (2002) 5637-5640
28. Young J., Biden K.G., Simms L.A., et al. HPP1. a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci U S A 98 (2001) 265-270
29. Shibata D, Zhang L, Cai K, et al. Tumor suppressor effects of HPP1 overexpression in colon cancer. Gastroenterology 2005;128:a-787.
30. Masuda N., Kato H., Nakajima T., et al. Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers. Cancer Sci 94 (2003) 612-617
31. Cai Y.C., Yang G.Y., Nie Y., et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas. loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 21 (2000) 683-689
32. Maley C.C., Galipeau P.C., Li X., et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64 (2004) 7629-7633
33. Heeren P.A., Kloppenberg F.W., Hollema H., et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 24 (2004) 2579-2583
34. Souza R.F. Molecular and biologic basis of upper gastrointestinal malignancy. esophageal carcinoma. Surg Oncol Clin N Am 11 (2002) 257-272 viii
35. Chiarugi V., Magnell L., Cinelli M., et al. Apoptosis and the cell cycle. Cell Mol Biol Res 40 (1994) 603-612
36. Meikrantz W., and Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 58 (1995) 160-174
37. Chawla-Sarkar M., Lindner D.J., Liu Y.F., et al. Apoptosis and interferons. role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
38. Akhtar M., Cheng Y., Magno R.M., et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 61 (2001) 2399-2403
39. Yang X., Xing H., Gao Q., et al. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 97 (2005) 413-421
40. Pyo H., Kim Y.B., Cho N.H., et al. Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 725-732
41. Meltzer S.J., Yin J., Manin B., et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 54 (1994) 3379-3382
42. Bian Y.S., Osterheld M.C., Fontolliet C., et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 122 (2002) 1113-1121
43. Okamoto A., Demetrick D.J., Spillare E.A., et al. p16INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harb Symp Quant Biol 59 (1994) 49-57
44. Kwong F.M., Tang J.C., Srivastava G., et al. Inactivation mechanisms and growth suppressive effects of p16INK4a in Asian esophageal squamous carcinoma cell lines. Cancer Lett 208 (2004) 207-213
45. Voorhoeve P.M., and Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4 (2003) 311-319
46. Carnero A., Hudson J.D., Price C.M., et al. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2 (2000) 148-155
47. Ceraline J., Deplanque G., Duclos B., et al. Relationships between p53 induction, cell cycle arrest and survival of normal human fibroblasts following DNA damage. Bull Cancer 84 (1997) 1007-1016
48. Hwang A., and Muschel R.J. Radiation and the G2 phase of the cell cycle. Radiat Res 150 (1998) S52-S59
49. Scolnick D.M., and Halazonetis T.D. CHFR defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406 (2000) 430-435
50. Satoh A., Toyota M., Itoh F., et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63 (2003) 8606-8613
51. Corn P.G., Summers M.K., Fogt F., et al. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene CHFR in colorectal and non-small cell lung cancer. Carcinogenesis 24 (2003) 47-51
52. Zhang L., Lu W., Miao X., et al. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis 24 (2003) 1039-1044
53. Hayashi H., Yazawa T., Okudela K., et al. Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res 93 (2002) 184-189
54. Miyazaki T., Kato H., Nakajima M., et al. An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. Br J Cancer 91 (2004) 1556-1560
55. Milas L., Milas M.M., and Mason K.A. Combination of taxanes with radiation. preclinical studies. Semin Radiat Oncol 9 (1999) 12-26
56. McCabe M.L., and Dlamini Z. The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 5 (2005) 1113-1130
57. Ghadimi B.M., Grade M., Difilippantonio M.J., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23 (2005) 1826-1838